Search Results | Blood | American Society of Hematology

1-20 of 583

2 3 4 5

Sort by

Sort Order Select

Journal Articles

Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation

Blood (2021) 137 (23): 3212–3217.

DOI: https://doi.org/10.1182/blood.2021010867

Published: 2021

Includes: Supplemental data

Journal Articles

3D Telomeric Fingerprint of Advanced Cutaneous T-Cell Lymphoma

Marc Nicolas Bienz, MD MSc, Cheryl Taylor-Kashton, Naciba Benlimame, PhD, Tina Petrogiannis-Haliotis, MD PhD, Kevin Pehr, MD, Sabine Mai, PhD, Hans Knecht, MD

Blood (2019) 134 (Supplement_1): 1501.

DOI: https://doi.org/10.1182/blood-2019-124559

Published: 2019

Journal Articles

Identification and Validation of Predictive Biomarkers to CD19- and BCMA-Specific CAR T-Cell Responses in CAR T-Cell Precursors

Blood (2019) 134 (Supplement_1): 622.

DOI: https://doi.org/10.1182/blood-2019-122513

Published: 2019

Journal Articles

Lisocabtagene Maraleucel (liso-cel) Manufacturing Process Control and Robustness across CD19+ Hematological Malignancies

Jeffrey Teoh, PhD, Timothy G. Johnstone, PhD, Brian Christin, BS, Rachel Yost, Neil A. Haig, Mary Mallaney, Aditya Radhakrishnan, Heidi H. Gillenwater, MD, Tina Albertson, MD, Paul Guptill, Lauren F. Brown, Christopher G. Ramsborg, Ronald J. Hause, PhD, Ryan P. Larson, PhD

Blood (2019) 134 (Supplement_1): 593.

DOI: https://doi.org/10.1182/blood-2019-127150

Published: 2019

Journal Articles

Integrated Immune Signature Analyses Identifies Evolution of Distinct Immunoregulatory Cell Populations Which Control Alloreactivity after Allogeneic HSCT

James Aries, Sarah Charrot, Jennifer Ball, Matthew Mee, Symeon Theocharidis, Sofie Van Gassen, Sameena Iqbal, John G. Gribben, MD DSc, Jeff Davies, MBBS, PhD

Blood (2019) 134 (Supplement_1): 595.

DOI: https://doi.org/10.1182/blood-2019-124875

Published: 2019

Journal Articles

A Combination Therapy with Dendritic Cells, Pomalidomide and Programmed Death-Ligand 1 Blockade Exerts a Potent Antitumor Immunity in a Murine Model of Multiple Myeloma

Je-Jung Lee, MD PhD, Tan-Huy Chu, Manh-Cuong Vo, Hye-Sung Park, Thangaraj Jaya Lakshmi, Seo-Yeon Ahn, MD, Ga-Young Song, Sung-Hoon Jung, MD, Hyeoung-Joon Kim, MD PhD

Blood (2019) 134 (Supplement_1): 1819.

DOI: https://doi.org/10.1182/blood-2019-127964

Published: 2019

Journal Articles

Response to Anti-Bcma CAR T Cell Therapy Correlates with T Cell Exhaustion and Activation Status in T Cells at Baseline in Myeloma

Meng Wang, BS, Iulian Pruteanu, PhD, Adam D. Cohen, MD, Alfred L. Garfall, MD, Lifeng Tian, PhD, Simon F Lacey, PhD, Joseph A Fraietta, PhD, Jennifer Brogdon, PhD, Megan Davis, PhD, Vanessa E. Gonzalez, Bruce L Levine, PhD, Don L. Siegel, MD PhD, Michael C. Milone, Edward A. Stadtmauer, MD FACP, Carl H June, MD, J. Joseph Melenhorst, PhD

Blood (2019) 134 (Supplement_1): 1909.

DOI: https://doi.org/10.1182/blood-2019-122396

Published: 2019

Journal Articles

Long-Term T Cell Expansion Results in Increased Numbers of Central Memory T Cells with Sustained Functional Properties for Adoptive T Cell Therapy

Stefanie Herda, PhD, Andreas Heimann, MSc, Stefanie Althoff, MSc, Josefine Ruß, Lars Bullinger, Dieter Beule, PhD, Benedikt Obermayer, PhD, Il-Kang Na, MD

Blood (2019) 134 (Supplement_1): 1943.

DOI: https://doi.org/10.1182/blood-2019-124736

Published: 2019

Journal Articles

Relative Contribution of Naïve and Memory T Cells to Alloreactivity in Hematopoietic Cell Transplantation

Esteban Arrieta-Bolaños, Maryam Mohamaddokht, Thuja Meurer, Pietro Crivello, Amin T. Turki, MD PhD, Peter A. Horn, Dietrich W. Beelen, J.H.Frederik Falkenburg, MD PhD, Katharina Fleischhauer, MD

Blood (2019) 134 (Supplement_1): 1923.

DOI: https://doi.org/10.1182/blood-2019-130273

Published: 2019

Journal Articles

CAR T Cells Derived from Healthy Mice Lead to Cytokine Release Syndrome (CRS) in the TCL1 Chronic Lymphocytic Leukemia Model; Mice with CLL Treated with Acalabrutinib or Ibrutinib Have Improved CAR T Cell Function without Increasing the Cytokines of CRS

Robin Sanderson, MRCP,FRCPath, Arantxa Romero-Toledo, MSc, John G. Gribben, MD DSc

Blood (2019) 134 (Supplement_1): 249.

DOI: https://doi.org/10.1182/blood-2019-125647

Published: 2019

Journal Articles

Restoring Innate and Adaptive Immune Repertoire in Multiple Myeloma for Therapeutic Application

Rafael Alonso Fernández, MD, Laetitia Pierre-Louis, Rao Prabhala, Yan Xu, MD, Joaquin Martinez-Lopez, MD PhD, Takahiro Miyazaki, Mehmet Kemal Samur, PhD, Loui Madakamutil, Mariateresa Fulciniti, PhD, Nikhil C. Munshi, MD

Blood (2019) 134 (Supplement_1): 4398.

DOI: https://doi.org/10.1182/blood-2019-128767

Published: 2019

Journal Articles

Simple, 1-Day Manufacturing of Quiescent Chimeric Antigen Receptor T Cells for Adoptive Immunotherapy

Saba Ghassemi, PhD, Roddy S O'Connor, PhD, Selene Nunez-cruz, PhD, Jai Patel, John Leferovich, Michael C. Milone

Blood (2019) 134 (Supplement_1): 4436.

DOI: https://doi.org/10.1182/blood-2019-131147

Published: 2019

Journal Articles

Evaluation of Bone Marrow CD8 + tissue-Resident Memory T Cells in Multiple Myeloma

Melania Carlisi, MD, Salvatrice Mancuso, MD, Marco Pio La Manna, Biologist, Valentina Orlando, Biologist, Nadia Caccamo, Prof, Sergio Siragusa, Prof, MD

Blood (2019) 134 (Supplement_1): 4389.

DOI: https://doi.org/10.1182/blood-2019-131349

Published: 2019

Journal Articles

Phase 1 Results of CNCT19: CD19 CAR Constructed of a New Anti-CD19 Chimeric Antigen Receptor in Relapsed or Refractory Acute Lymphoblastic Leukemia

Blood (2019) 134 (Supplement_1): 2622.

DOI: https://doi.org/10.1182/blood-2019-125342

Published: 2019

Journal Articles

Phase 1 Trial of Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocytic Leukemia

Milos D. Miljkovic, MDMSc, Kevin C Conlon, MD, Jennifer Hsu, RN, Clare Sun, MD, Adrian Wiestner, MD PhD, Thomas A. Waldmann, MD

Blood (2019) 134 (Supplement_1): 3052.

DOI: https://doi.org/10.1182/blood-2019-130807

Published: 2019

Journal Articles

Application of a Standardized Flow Cytometry Panel for Defining and Monitoring the Immunophenotype of CAR-T Cells

Irene Scarfò, PhD, Kathleen Gallagher, Marcela V. Maus, MD PhD, Rebecca Larson, BS, Maegan Sheehan, BS, Gabrielle Brini, MSc, Scott Bornheimer, Mary Beth Hanley, Matthew Frigault, MD MSc, Mark Leick, MD, Alena Chekmasova, PhD

Blood (2019) 134 (Supplement_1): 5626.

DOI: https://doi.org/10.1182/blood-2019-128745

Published: 2019

Journal Articles

Safety and Preliminary Clinical Activity of REGN5458, an Anti-Bcma x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma

Dennis Cooper, MD, Deepu Madduri, MD, Suzanne Lentzsch, MD PhD, Sundar Jagannath, Jingjin Li, PhD, Anita Boyapati, PhD, Lieve Adriaens, PharmD, Dhruti Chokshi, BS, Min Zhu, PhD, Israel Lowy, MD PhD, David M. Weinreich, MD, George D. Yancopoulos, MD PhD, Manish Sharma, MD, Maria Karasarides, PhD, David Sternberg, MD PhD

Blood (2019) 134 (Supplement_1): 3176.

DOI: https://doi.org/10.1182/blood-2019-126818

Published: 2019

Journal Articles

Large-Scale Manufacturing of CMV-CD19CAR T Cells and Characterization of Their Biologic and Immunologic Properties

Xiuli Wang, PhD, Miriam Walter, Ryan Urak, Laura Lim, Vibhuti Vyas, MS, Sally Mokhtari, PhD, Don J. Diamond, PhD, Angelo Cardoso, PhD, John Zaia, MD, Stephen J. Forman, MD, Ryotaro Nakamura, MD

Blood (2019) 134 (Supplement_1): 3247.

DOI: https://doi.org/10.1182/blood-2019-131843

Published: 2019

Journal Articles

Transgenic Expression of IL15 in CD123-Specific BiTE-Secreting Engager T-Cells Results in Improved Anti-AML Activity

Hong Mu-Mosley, MD PhD, Lauren B Ostermann, Muharrem Muftuoglu, MD, Wendy Schober, Nalini B Patel, Abishek Vaidya, MS, Challice L. Bonifant, MD PhD, Stephen Gottschalk, MD, Mireya Paulina Velasquez, MD, Michael Andreeff, MD PhD

Blood (2019) 134 (Supplement_1): 3917.

DOI: https://doi.org/10.1182/blood-2019-125928

Published: 2019

Journal Articles

Blinatumomab-Induced T Cell Activation at Single Cell Transcriptome Resolution

Hong Yin, MD PhD, Yi Huo, PhD, Zhen Sheng, PhD, Chi-Ming Li, PhD, Daniel C Ellwanger, PhD, Daniel Lu, PhD, Oliver Homann, PhD, Songli Wang, MD PhD, Ruibao Ren, MD PhD

Blood (2019) 134 (Supplement_1): 3886.

DOI: https://doi.org/10.1182/blood-2019-124636

Published: 2019

2 3 4 5

NARROW

Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation

3D Telomeric Fingerprint of Advanced Cutaneous T-Cell Lymphoma

Identification and Validation of Predictive Biomarkers to CD19- and BCMA-Specific CAR T-Cell Responses in CAR T-Cell Precursors

Lisocabtagene Maraleucel (liso-cel) Manufacturing Process Control and Robustness across CD19+ Hematological Malignancies

Integrated Immune Signature Analyses Identifies Evolution of Distinct Immunoregulatory Cell Populations Which Control Alloreactivity after Allogeneic HSCT

A Combination Therapy with Dendritic Cells, Pomalidomide and Programmed Death-Ligand 1 Blockade Exerts a Potent Antitumor Immunity in a Murine Model of Multiple Myeloma

Response to Anti-Bcma CAR T Cell Therapy Correlates with T Cell Exhaustion and Activation Status in T Cells at Baseline in Myeloma

Long-Term T Cell Expansion Results in Increased Numbers of Central Memory T Cells with Sustained Functional Properties for Adoptive T Cell Therapy

Relative Contribution of Naïve and Memory T Cells to Alloreactivity in Hematopoietic Cell Transplantation

CAR T Cells Derived from Healthy Mice Lead to Cytokine Release Syndrome (CRS) in the TCL1 Chronic Lymphocytic Leukemia Model; Mice with CLL Treated with Acalabrutinib or Ibrutinib Have Improved CAR T Cell Function without Increasing the Cytokines of CRS

Restoring Innate and Adaptive Immune Repertoire in Multiple Myeloma for Therapeutic Application

Simple, 1-Day Manufacturing of Quiescent Chimeric Antigen Receptor T Cells for Adoptive Immunotherapy

Evaluation of Bone Marrow CD8 + tissue-Resident Memory T Cells in Multiple Myeloma

Phase 1 Results of CNCT19: CD19 CAR Constructed of a New Anti-CD19 Chimeric Antigen Receptor in Relapsed or Refractory Acute Lymphoblastic Leukemia

Phase 1 Trial of Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocytic Leukemia

Application of a Standardized Flow Cytometry Panel for Defining and Monitoring the Immunophenotype of CAR-T Cells

Safety and Preliminary Clinical Activity of REGN5458, an Anti-Bcma x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma

Large-Scale Manufacturing of CMV-CD19CAR T Cells and Characterization of Their Biologic and Immunologic Properties

Transgenic Expression of IL15 in CD123-Specific BiTE-Secreting Engager T-Cells Results in Improved Anti-AML Activity

Blinatumomab-Induced T Cell Activation at Single Cell Transcriptome Resolution

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only